Skip to Main Content
Skip Nav Destination

This chapter covers the identification and characterization of the novel Hsp90 inhibitor NVP-AUY922, which entered clinical trials in July 2007. The program leading to the identification of NVP-AUY922 (VER-52296) used complementary hit ID technologies such as HTS and fragment-based screening, relied heavily on structure-based design and required the design of new assays and probes to drive the compound optimization. In vivo characterization in tumor-bearing animals assisted in compound selection for pre-clinical studies.

You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal